NATCO announces Launch of First Generic Version of Pomalyst® Capsules in the Australian Market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the launch of first generic version of Pomalyst® (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO's commercial partner Juno Pharmaceuticals Pty Ltd.

Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. For more information refer to the full prescribing information or other medical resources.

Pomalyst® registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 613.20 as compared to the previous close of Rs. 621.15. The total number of shares traded during the day was 17745 in over 1270 trades.

The stock hit an intraday high of Rs. 623.75 and intraday low of 610.35. The net turnover during the day was Rs. 10966671.00.

Pomalyst® is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners

Source : Equity Bulls

Keywords

INE987B01026 NATCOPharma Pomalyst PomalidomideCapsules Australia ProductLaunch